MedinCell (MEDCL) H.C. Wainwright 27th Annual Global Investment Conference summary

Strategic growth engines

• UZEDY, the first commercial product, was approved in 2023 and is driving operational profitability.

• Olanzapine LAI, developed with Teva, is expected to accelerate growth and targets a large unmet market due to previous product limitations.

• R&D pipeline includes a major partnership with AbbVie and ongoing technology innovation.

Product performance and market opportunity

• UZEDY targets a €4.8 billion long-acting injectable antipsychotic market, showing strong prescription trends and €117 million in 2024 sales.

• Real-world data shows UZEDY reduces relapse rates, inpatient stays, and costs by up to 29%.

• FDA feedback on UZEDY's extension to bipolar disorder is expected by year-end.

• Olanzapine LAI completed phase 3, with FDA filing planned by year-end and potential launch in 2026.

• Both UZEDY and olanzapine LAI have long patent lives, expiring in 2042 and 2044, respectively.

Pipeline and partnerships

• Pipeline includes a local celecoxib release for post-op pain, a six-month contraceptive, and a malaria initiative.

• Major deal with AbbVie in 2024 includes up to six LAI programs and €1.9 billion in potential milestones.

• Early-stage pipeline spans five therapeutic areas, with several programs having blockbuster potential.